Uberti Elza Maria Hartmann, Fajardo Maria do Carmo, da Cunha Adriana Gerhardt Vieira, Frota Sirlene Soares, Braga Antônio, Ayub Antonio Celso Koehler
Trophoblastic Disease Center, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil.
Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil.
Rev Bras Ginecol Obstet. 2015 Jun;37(6):258-65. doi: 10.1590/SO100-720320150005366.
To compare two single-agent chemotherapy (ChT) regimens evaluating, in first-line treatment, response and side effects and, in final single-agent treatment, the outcomes, among Brazilian patients with low-risk gestational trophoblastic neoplasia (GTN), according to International Federation of Gynecology and Obstetrics (FIGO) 2002.
Retrospective analysis of two concurrent cohorts with 194 low-risk GTN patients: from 1992 to 2012, as first-line treatment, 115 patients received 4 intramuscular doses of methotrexate alternated with 4 oral doses of folinic acid (MTX/FA) repetead every 14 days and, since 1996, 79 patients received an endovenous bolus-dose of actinomycin D (Act-D), biweekly. At GTN diagnosis, patient opinion was taken into consideration when defining the initial single-agent ChT regimen, and when there was resistance or toxicity to one regimen, the other drug was used preferentially. This study was approved by the Irmandade da Santa Casa de Misericórdia de Porto Alegre Ethical Committee.
Both groups were clinically similar (p>0.05). In first-line treatments, frequency of complete response was similar (75.7% with MTX/FA and 67.1% with bolus Act-D); the number of ChT courses -median 3 (range: 1-10) with MTX/FA and 2 (range: 1-6) with bolus Act-D - and the time to remission -median 9 weeks (range: 2-16) with MTX/FA and 10 weeks (range: 2-16) with bolus Act-D) - were not different between the groups. In both groups, first-line side effects frequency were high but intensity was low; stomatitis was higher with MTX/FA (p<0.01) and nausea and vomit with Act-D (p<0.01). Final single-agent ChT responses were high in both groups (94.8% with MTX/FA and 83.5% with bolus Act-D; p<0.01) and 13% higher in the group initially treated with MTX/FA. Rates of hysterectomy and of GTN recurrence were low and similar. No patient died due to GTN.
The two regimens had similar first-line ChT response. Final single-agent response rates were high and similar in both groups but the final single-agent remission rate was higher in the MTX/FA group.
根据国际妇产科联盟(FIGO)2002年标准,比较两种单药化疗(ChT)方案用于巴西低风险妊娠滋养细胞肿瘤(GTN)患者一线治疗时的疗效和副作用,以及最终单药治疗时的结局。
对两个同时期队列中的194例低风险GTN患者进行回顾性分析:1992年至2012年,115例患者作为一线治疗,每14天接受4次肌内注射甲氨蝶呤并交替4次口服亚叶酸(MTX/FA);自1996年起,79例患者每两周接受一次静脉推注放线菌素D(Act-D)。在GTN诊断时,确定初始单药ChT方案时考虑患者意见,当对一种方案出现耐药或毒性时,优先使用另一种药物。本研究经阿雷格里港圣卡塔琳娜慈善会伦理委员会批准。
两组在临床上相似(p>0.05)。在一线治疗中,完全缓解率相似(MTX/FA组为75.7%,推注Act-D组为67.1%);ChT疗程数——MTX/FA组中位数为3(范围:1 - 10),推注Act-D组中位数为2(范围:1 - 6)——以及缓解时间——MTX/FA组中位数为9周(范围:2 - 16),推注Act-D组中位数为10周(范围:2 - 16)——两组之间无差异。两组一线副作用发生率均较高但强度较低;MTX/FA组口腔炎发生率较高(p<0.01),Act-D组恶心和呕吐发生率较高(p<0.01)。两组最终单药ChT缓解率均较高(MTX/FA组为94.8%,推注Act-D组为83.5%;p<0.01),且初始接受MTX/FA治疗的组高出13%。子宫切除率和GTN复发率较低且相似。无患者因GTN死亡。
两种方案一线ChT疗效相似。两组最终单药缓解率均较高且相似,但MTX/FA组最终单药缓解率更高。